Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a 24-year-old patient with severe alopecia areata showed an excellent clinical response to the JAK inhibitor tofacitinib after one month, following unsuccessful previous treatments.

Infliximab may cause hair loss in Crohn's disease patients.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This article discusses the authors' concerns over the misinterpretation of studies linking smoking and frontal fibrosing alopecia, clarifying that neither study suggests smoking is protective against the condition.

In this retrospective study, tofacitinib showed promise as a treatment for alopecia areata, with 46.5% of patients experiencing a very good response and minimal adverse effects, suggesting it could be a primary option for moderate to severe cases.

This study introduces ALUDWIG, an automated tool for assessing female androgenic alopecia severity from smartphone images, which may offer a more consistent alternative to current scoring methods like the Ludwig scale.

This article appears to be a table of contents or navigation page for a journal, not presenting any new findings or research results.

This study found that the small signaling peptide RALF22 plays a key role in root hair growth response to volatile compounds emitted by Penicillium aurantiogriseum through ethylene, auxin, and photosynthesis signaling in Arabidopsis.

This study found that the STRIAA scoring tool provides a rapid and highly reliable assessment of alopecia areata severity, showing a significant correlation with the traditional SALT score, thus enhancing clinical evaluation in patients with this condition.

This review presents an objective analysis of female androgenetic alopecia, discussing clinical and dermoscopic examination approaches but reports no new clinical findings.

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.

This study found that higher Dietary Inflammatory Index scores were significantly associated with an increase in both the occurrence and severity of alopecia areata.

This study found that alopecia areata significantly impacts patients' quality of life irrespective of hair loss severity, and concluded that the newer assessment tools AAPPO and AASIS better capture this impact compared to the traditional SALT measure.

In this study, the researchers observed that treatment with intralesional and topical corticosteroids, finasteride, and minoxidil may stop the progression of frontal fibrosing alopecia in postmenopausal and premenopausal women.

In this case report, the researchers described the use of tofacitinib in treating a 14-year-old boy from India with severe alopecia areata, achieving complete hair regrowth within 2 months without serious adverse events, highlighting tofacitinib's potential benefits and safety in adolescent cases.

This review discusses the possible immune-mediated and environmental factors contributing to frontal fibrosing alopecia but reports no new clinical findings, emphasizing the need for standardized treatment evaluations.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

In this study, researchers developed a novel topical gel combining minoxidil and JAK inhibitor tofacitinib, which effectively enhanced hair follicle growth and reduced local inflammation in mice with alopecia areata, suggesting a new approach for treating this condition.

This review covers the current status of the interstitial pneumonia with autoimmune features (IPAF) category, pointing out the need for revision of its criteria to establish it as a standalone diagnostic term, but reports no new clinical findings.

AI can accurately measure hair loss severity in alopecia areata.

This study observed that inflammation in androgenetic alopecia samples was similar to alopecia areata controls, but infundibular and isthmic inflammation were significantly more common in androgenetic alopecia cases.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

This review discusses frontal fibrosing alopecia, noting its frequent misdiagnosis and highlighting the need for larger studies to better understand its epidemiology, causes, and treatment options; it reports no new clinical findings.

This study identified significant genetic associations with frontal fibrosing alopecia at four genomic loci, suggesting it is a genetically predisposed immuno-inflammatory disorder influenced by the HLA-B*07: 02 allele.

The researchers in this study identified molecular mechanisms involved in frontal fibrosis alopecia, highlighting immune response and fatty acid metabolism, and developed a four-gene diagnostic model showing high accuracy in distinguishing affected individuals from controls.

This study identifies specific trichoscopic features such as empty follicles and perifollicular erythema in Caucasians with frontal fibrosing alopecia, which may assist in diagnosis and monitoring, but stresses the need for further research due to limited demographic data.

This study adds evidence suggesting a genetic component to frontal fibrosing alopecia, with daughters experiencing an earlier onset than their mothers, although the clinical pattern remains similar to non-familial cases.